Organization | Shiga University

Shiga University Report issue

Academic/Hospital Phase 1 Phase 2 Phase 4

Founded: Hikone Japan (1949)

Organization Overview

First Clinical Trial

2003

NCT00202618

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2012

Timeline

NOW

Now

Alternative names

Department of Medical Oncology, Shiga University of Medical Science | Shiga University of Medical Science Hospital

Active Ingredients

Drugs in Phase 4 Trials (3)

aliskiren (tekturna) (1 trial)

amlodipine (norvasc) (1 trial)

valsartan (diovan) (1 trial)

Drugs in Phase 2 Trials (4)

hla-a*0201restricted urlc10 peptides with adjuvant (1 trial)

hla-a*2402 or a*0201 restricted peptides (1 trial)

hla-a*2402restricted urlc10, cdca1, and kif20a peptides with adjuvant (1 trial)

s-488410 (1 trial)

Drugs in Phase 1 Trials (3)

hla-a*0201 or hla-a*0206-restricted urlc10 peptides (1 trial)

hla-a*2402-restricted cdca1 and kif20a peptides (1 trial)

hla-a*2402restricted urlc10, cdca1, and kif20a peptides (1 trial)

Drugs in Other Trials (2)

hepatitis b immune globulin (human) (BayHep B) (1 trial)

pioglitazone (actos) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Albuminuria (Phase 4)

Carcinoma, Non-Small-Cell Lung (Phase 2)

Diabetes Mellitus (Phase 4)

Diabetes Mellitus, Type 2 (Phase 4)

Hypertension (Phase 4)

Lung Neoplasms (Phase 2)

Neoplasms (Phase 2)

Small Cell Lung Carcinoma (Phase 1)

Overview

Highest Phase: Phase 4
# of Trials: 10
# of Trial APIs: 12